Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.
about
Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studiesTherapeutic targeting of aldosterone: a novel approach to the treatment of glomerular diseaseThe role of the renin-angiotensin-aldosterone system in the pathobiology of pulmonary arterial hypertension (2013 Grover Conference series)Is there a new dawn for selective mineralocorticoid receptor antagonism?Primary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney.30 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development.Interfering with mineralocorticoid receptor activation: the past, present, and futureNew drug therapies interfering with the renin-angiotensin-aldosterone system for resistant hypertension.Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney diseasSuppression of Rapidly Progressive Mouse Glomerulonephritis with the Non-Steroidal Mineralocorticoid Receptor Antagonist BR-4628.Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity.Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease.New agents modulating the renin-angiotensin-aldosterone system-Will there be a new therapeutic option?Microwave-assisted protection of primary amines as 2,5-dimethylpyrroles and their orthogonal deprotection.Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy.Targeting the mineralocorticoid receptor in cardiovascular disease.Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte.Mineralocorticoid receptor modulators: a patent review (2007 - 2012).Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents.Aldosterone excess and resistant hypertension: investigation and treatment.Novel drug mechanisms in development for heart failure.Newest additions to heart failure treatment.Novel RAAS agonists and antagonists: clinical applications and controversies.New developments in the pharmacological treatment of hypertension: dead-end or a glimmer at the horizon?Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.New medical therapies for heart failure.Future drug discovery in renin-angiotensin-aldosterone system intervention.Treatment of Hyperkalemia in Heart Failure.Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease.The safety of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure.Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.Computational Chemistry in the Pharmaceutical Industry: From Childhood to Adolescence.Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.Deletion of the Mineralocorticoid Receptor in Myeloid Cells Attenuates Central Nervous System Autoimmunity.Influence of renal impairment on aldosterone status, calcium metabolism, and vasopressin activity in outpatients with systolic heart failure.Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies.
P2860
Q26746907-37159A58-F326-4891-8B7E-3C021932547FQ26996385-A2C0E68D-9944-4031-9E64-323F1F94837AQ27013946-60213DF5-48D5-4B0B-92F6-81ECA36C5AB8Q27027792-D2386437-3C32-4FDF-B3E6-C7357AB8DF44Q30248429-A7AF59AD-89CA-4A32-B9BF-75EA3B99C7B1Q33846431-F8D31FE7-5549-4450-9C44-0561F0644520Q34019947-C312F7B0-6C5A-4EBE-987A-4EB2E1706CCBQ34384580-649D342B-5652-4737-BEBF-374DD7DE17ACQ34462504-ED8A374B-5A5B-4E8B-A260-3E590F15AE41Q35877719-77155E54-799C-4E52-BA6A-8CAC37AB0255Q36206559-4628E87A-233D-42FB-B9BD-452D351F61E6Q36437145-BA9C468C-51B0-41F7-9A15-62D6FBA55C9AQ37094366-FC94EA63-9755-42E0-8A9B-5D99F89107F7Q37098407-505C1D07-8F73-4B94-BEC6-8A00F7EE8D2FQ37347190-7BD9E536-15CC-4BDA-A840-1BAD50C6E143Q37363526-8C1D8979-CB64-44CB-8C93-8FD6C0BB63E8Q37720499-712098D4-84D6-4761-973B-3A9DF6B7E9F9Q38074488-EF74BEF6-3BCE-4CB8-987B-73BEC18C88DBQ38119546-1CB5D959-FB88-40F7-8399-3F28F62AC490Q38161538-F8BD1751-930E-4DA8-90EF-C8CF5C0A96CAQ38181208-DC925AB9-60C7-4830-978C-9AA7987702AAQ38208961-56CF9108-A784-4B32-9752-F7E9D39454A1Q38209074-F242893C-5192-48C1-9DD9-10B146975C88Q38225739-186AFD19-E498-4551-8DC6-25B50A5F1872Q38349798-ED3E5DE2-851A-490D-B99E-8CEFF88DA6FEQ38429870-1B950982-0AB1-4F88-A1AA-59983683D674Q38533385-5BD381FA-AA78-4998-9EE9-D123867BD2E0Q38594785-4306767B-84DA-4AA7-B490-1FA120868D63Q38679303-CE58B448-42D3-420A-8E29-6DDBAD7DB592Q38705827-25306D0C-DD46-4C04-AB55-7958E546E823Q38750210-3A9855A6-E827-4E40-95DA-524D0029FEA6Q38766590-B7E389AB-6050-4DAB-BC83-F02C807C9692Q38817871-23D21E9C-C134-4AD2-84A8-13DA4DDC7C2BQ38850114-5AA8FAED-D942-45C7-A6AB-D6C97C41A1CFQ38965181-6DFFF8FF-F489-4D93-B3C5-D39FA0D3A0BDQ39199991-83166EC9-34A1-4BD2-830B-555729692CCCQ41677231-20D6C2E6-60C1-4071-B92B-F17CEC574F10Q47120039-5AE73A97-7A24-4C28-A962-88D3EEDB3D63Q47575429-D96B53EF-5361-4415-9CEF-EAB31F3BF369Q51293660-2BEFC734-5212-41E1-9369-812D09312EF1
P2860
Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.
@en
Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.
@nl
type
label
Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.
@en
Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.
@nl
prefLabel
Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.
@en
Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.
@nl
P2093
P2860
P356
P1433
P1476
Discovery of BAY 94-8862: a no ...... tment of cardiorenal diseases.
@en
P2093
Adam Nitsche
Alexander Hillisch
Alexander Kuhl
Heike Gielen-Haertwig
Heike Heckroth
Holger Paulsen
Jens-Kerim Ergüden
Joachim Mittendorf
Johannes Platzek
Karl-Heinz Schlemmer
P2860
P304
P356
10.1002/CMDC.201200081
P577
2012-07-12T00:00:00Z